Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

bionpharma inc., - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules is indicated for the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant  [see clinical studies ( 14.1)] , liver transplants  [see clinical studies ( 14.2)]  and heart transplant  [see clinical studies ( 14.3)] , in combination with other immunosuppressants. tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. tacrolimus injection is contraindicated in patients with a hypersensitivity to hco-60 (polyoxyl 60 hydrogenated castor oil). hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see adverse reactions ( 6)] . pregnancy exposure registry there is a pregnancy registry that monitors pregnancy outcomes in women exposed to tacrolimus during pregnancy. the transplantation pregnancy registry

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

panacea biotec limited - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules is indicated for the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant  [see clinical studies ( 14.1)] , liver transplants  [see clinical studies ( 14.2)]  and heart transplant  [see clinical studies ( 14.3)] , in combination with other immunosuppressants. tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. tacrolimus injection is contraindicated in patients with a hypersensitivity to hco-60 (polyoxyl 60 hydrogenated castor oil). hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see adverse reactions ( 6)] . pregnancy exposure registry there is a pregnancy registry that monitors pregnancy outcomes in women exposed to tacrolimus during pregnancy. the transplantation pregnancy registry

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.3 mg in 1 g - tacrolimus ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). tacrolimus ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 1 mg - tacrolimus capsules, usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. it is recommended that tacrolimus capsules be used concomitantly with azathioprine or mycophenolate mofetil (mmf) and adrenal corticosteroids [see clinical studies (14.1)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules [see dosage and administration (2.6)]. tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. it is recommended that tacrolimus capsules be used concomitantly with adrenal corticosteroids [see clinical studies (14.2)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules [see dosage and administration (2.6)] . tacrolimus capsules are indicated for the prophylaxis of organ rejection in patients receiving allogeneic heart transplants. it is recommended that tacrolimus capsules be used concomitantly with azathioprine o

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

belcher pharmaceuticals,llc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules is indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. it is recommended that tacrolimus be used concomitantly with azathioprine or mycophenolate mofetil (mmf) and adrenal corticosteroids [see clinical studies ( 14.1)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus [see dosage and administration ( 2.6)]. tacrolimus capsules is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. it is recommended that tacrolimus be used concomitantly with adrenal corticosteroids [see clinical studies ( 14.2)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus [see dosage and administration ( 2.6)]. tacrolimus capsules is indicated for t

Կանադա - անգլերեն - Health Canada

jamp pharma corporation - tacrolimus - capsule (immediate release) - 0.5mg - tacrolimus 0.5mg - immunosuppressive agents

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 1.02 mg (equivalent: tacrolimus, qty 1 mg) - capsule - excipient ingredients: hypromellose; dichloromethane; lactose; ethanol absolute; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 0.51 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule - excipient ingredients: dichloromethane; lactose; ethanol absolute; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 5.1 mg (equivalent: tacrolimus, qty 5 mg) - capsule - excipient ingredients: dichloromethane; lactose; magnesium stearate; croscarmellose sodium; ethanol absolute; hypromellose; titanium dioxide; purified water; iron oxide red; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

strides pharma science limited - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules are indicated for the prophylaxis of organ rejection, in adult patients receiving allogeneic kidney transplant [see clinical studies (14.1)], liver transplant [see clinical studies (14.2)] or heart transplant [see clinical studies (14.3)] and pediatric patients receiving allogeneic liver transplant [see clinical studies (14.2)] in combination with other immunosuppressants. tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. tacrolimus injection is contraindicated in patients with a hypersensitivity to hco-60 (polyoxyl 60 hydrogenated castor oil). hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see adverse reactions (6)] . risk summary tacrolimus can cause fetal harm when administered to a pregnant woman. data from postmarketing surveillance and tpri suggest that infants exposed to tacrolimus in utero are at a risk of prematurity, birth defects/congenital anomalies, low birth weight, and